Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Liposoma Health B V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located in 1 distinct art unit. This represents a highly focused and singular prosecution effort at this time. The involvement of 1 distinct art unit means the practitioner only needs to account for the specific guidelines of one patent office division.
The busiest examiner, PEEBLES, KATHERINE, is responsible for 1 busiest examiner pending action. This figure is identical to the total of 1 pending office action for the company. Consequently, the prosecution of the entire active portfolio is currently in the hands of this single examiner. The 1 busiest examiner pending action managed by PEEBLES, KATHERINE will determine the immediate outcome for this portfolio.
Practitioners should focus on the 1 busiest examiner pending action by understanding the specific examination style of PEEBLES, KATHERINE. This singular focus allows for a deep dive into the examiner's specific preferences to resolve the 1 pending office action. Success for the 1 busiest examiner pending action will depend on meeting the specific requirements of the 1 distinct examiner in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 1 | 35.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690807 | LIPID FORMULATIONS FOR THE PREPARATION OF HEALTH INGREDIENT-CONTAINING HOT DRINKS | PEEBLES, KATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690807 | LIPID FORMULATIONS FOR THE PREPARATION OF HEALTH INGREDIENT-CONTAINING HOT DRINKS | PEEBLES, KATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690807 | LIPID FORMULATIONS FOR THE PREPARATION OF HEALTH INGREDIENT-CONTAINING HOT DRINKS | PEEBLES, KATHERINE | 1617 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLiposoma Health B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine Peebles has the most, with 1 of Liposoma Health B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
